François Ghiringhelli: Novel Biomarkers of response to checkpoint inhibitors and rational of chemoimmunotherapy combination

Dates de l'évènement : 15/03/2018 13:00
Organisateur : Daniel Olive
Lieu : IPC2
Catégorie : Séminaires externes

Centre Georges Francois Leclerc, Dijon



Checkpoints inhibitors are in the way to change cancer therapy. However such therapies are effective only in a subset of patients and biomarkers are unmet need. The future of immunotherapy evolve to combination of chemotherapies and immunotherapy. In this seminar we will show how to generate multidimential biomarker in a cohort of patients treated for a lung cancer by anti PD1 mAb. Then we will show how can we use chemotherapy to enhance the efficacy of immunotherapy in digestive cancer.



References :

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F.

Oncoimmunology. 2017 Jun 16;6(9):e1339856. doi: 10.1080/2162402X.2017.1339856. eCollection 2017. PMID:28932641


Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F.

Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2. PMID: 23202296



Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F.

Cancer Res. 2016 Sep 15;76(18):5241-52. doi: 10.1158/0008-5472.CAN-15-3164. Epub 2016 Aug 5. PMID: 27496709